Jianjun Chen

44PUBLICATIONS
25CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsMolecular targetsInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Industrial molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Sep 10, 2026
Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity.

|Aug 19, 2026
Discovery of Aurora A/HDAC dual-target inhibitors: broad-spectrum in vitro antitumor activity and in vivo pharmacokinetic limitations.

|Mar 08, 2026
Novel Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors Modulate Lipid Metabolism for Enhanced Tumor Immunotherapy.

Zichao Yang, Ziqing Liu, Jiayi Zhou

|Feb 17, 2026
Exogenous Epstein-Barr virus nuclear antigen 1 induces ADAR1-driven tumor resistance against immunotherapy.

Changlin Liu, Zhiqiang Sun, Chao Li

|Dec 04, 2025
Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8+ Effector T‑Cell Function for Synergistic Cancer Immunotherapy.

Keyi Ao, Zhiqiang Sun, Yi Hao

|Aug 15, 2025
Discovery of Rigid Linker-Based IRAK4 PROTACs with Improved Metabolic Stability for the Treatment of Inflammatory Diseases.

Yapeng Fan, Rongxiang Ma, Kabonde Makasa Njobvu

Pageof 8

Frequent Collaborators

4 joint publications

Shuwen Liu

4 joint publications

Xiaopeng Peng

3 joint publications

Yingfeng Tu

3 joint publications

Binbin Cheng